While α‐LDLR slowed tumor growth with a TGI of 40.2% over the immunoglobin G (IgG) control, concurrent LDLR blockade significantly weakened the anti‐tumor efficacy of OxPt/SN38 treatment with a TGI of 51.6% compared to a TGI of 91.2% for OxPt/SN38 treatment with control IgG injection. Here, LDLR is linked to neoplasm.